invIOs GmbH

invIOs is a privately held biotech company based in Vienna, Austria, focused on the discovery and development of innovative cancer immunotherapies. The proprietary cell therapy technology platform for the silencing of intracellular IO targets, enables rapid treatment of patients using their own cells, by employing short out-of-body times in an out-patient setting. The novel concept allows access to and treatment for indications that had not previously been addressable by cell therapy.

APN401 is the first clinically validated candidate based on the cell therapy platform. The clinical program is a first-in-class ambulatory autologous transient cell therapy to strengthen immune reactivity via an intracellular master checkpoint inhibitor, Cbl-b. It is currently being evaluated in a Phase 1b clinical trial in patients with advanced-stage solid tumors.

The second candidate of the platform is INV441, an early-stage cell therapy approach aiming to activate tumor-associated immune cells.

Thirdly, the orally administered small molecule candidate INV501 is being developed to target tumor-specific immune activation via this different entry-point.